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Abstract
Background: Methamphetamine (MA) use remains a major public health concern around the world. Recent findings suggest that
buprenorphine may be helpful for cocaine use reduction. Moreover, animal studies described reduced dopamine peak effect fol-
lowing MA use, due to the administration of low dose buprenorphine.
Objectives: This study examined the effectiveness of buprenorphine with brief cognitive behavioral therapy on MA use disorder.
Methods: The study was conducted in an outpatient substance abuse treatment center in Qazvin, Iran. Nineteen MA users received
buprenorphine for 24 weeks combined with brief cognitive behavioral therapy in an outpatient substance abuse treatment pro-
gram, three times per week, as a before and after non - randomization study. Clinical outcomes included treatment retention, MA
use, degree of MA dependency and craving, quality of life, cognitive abilities questionnaire, addiction severity and also adverse
events. Data was analyzed by performing repeated measures analysis and the Friedman test for nonparametric variables.
Results: Fifteen participants completed the study during six months and frequency of MA use was significantly decreased at 24
weeks (P < 0.001). There were also significant reductions in craving (P < 0.001), degree of MA dependence (P < 0.001), and improve-
ments in quality of life, cognitive ability, and some subscales of addiction severity.
Conclusions: The results of this preliminary clinical study demonstrated that buprenorphine could potentially attenuate MA crav-
ing and alternate rewarding effects of MA and had promising effects on cognitive impairment. Furthermore, buprenorphine can be
considered as a harm reduction intervention in some communities, in which the people, as a result of cultural beliefs, do not accept
a therapy, which only consists of counseling and no medications.
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1. Background
Methamphetamine (MA) use remains a major public
health burden globally. It is estimated that approximately
52 million individuals aged 15 to 64 years old, worldwide,
have used amphetamine - type stimulants, such as ecstasy,
amphetamine, and MA. However, although the use of ec-
stasy has remained stable in the recent years, the use of
MA has increased by approximately 85% (1). Furthermore,
MA use not only increases the risk for high risk sexual be-
haviors, yet it also reduces the effectiveness of Methadone
Maintenance Treatment (MMT) (2, 3); it has been estimated
that 20% to 60% of MMT patients in Iran use MA (4, 5).
Methamphetamine use is accompanied by both struc-
tural and functional changes in the brain that lead to im-
pairment in executive function (6). Cognitive squeal fol-
lowing MA use may also reduce the efficacy of psycholog-
ical interventions, such as the Matrix model (7). Moreover,
MA use is also associated with high levels of craving and
rates of relapse.
Numerous studies have been performed evaluating
the impact of different medications in reducing MA crav-
ing. Bupropion and naltrexone have demonstrated some
promising findings in reducing cravings for amphetamine
in randomized controlled trials (8, 9). However, there is
no approved and effective medication that contributes to
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long - term abstinence for recovery from MA use disorders.
Recent animal studies have demonstrated encourag-
ing findings of buprenorphine in attenuating the effect of
MA; a study done on adult rats injected with subcutaneous
buprenorphine revealed shortened periods of dopamine
release and reduced MA - induced dopamine peak - ef-
fects (10). Furthermore, buprenorphine - exposed rats were
found to have significantly reduced MA - related behav-
iors and cocaine self - administration (11, 12). Moreover,
a randomized clinical study in Iran, which was held be-
tween participants, who were enrolled in Matrix therapy
program, described significantly reduced cravings to MA
use among participants that received buprenorphine com-
pared with the placebo (13).
Preliminary evidence suggests that buprenorphine
may offer a novel approach for the treatment of MA use dis-
order. This research was an observational study to investi-
gate the efficacy of buprenorphine treatment in MA users.
2. Objectives
This study aimed at assessing the effectiveness of
buprenorphine with brief cognitive behavioral therapy for
the treatment of MA use disorder among MA users in the
city of Qazvin, Iran.
3. Materials andMethods
3.1. Designs and Sites
The study was designed as a before and after non - ran-
domization study in an outpatient substance abuse treat-
ment center in Qazvin. Ethical approval was obtained
from Tehran University of Medical Sciences Research Ethics
Committee (ethical approval code: 130/322/93/S) and regis-
tered at the Iranian Registry of Clinical Trials (IRCT).
3.2. Participants
Nineteen participants were recruited from an outpa-
tient substance abuse treatment program in Qazvin, be-
tween July 2014 and June 2015, and provided an informed
consent. Inclusion criteria included diagnosis of MA de-
pendency, according to the Diagnostic and Statistical Man-
ual of Mental Disorders four edition (DSM IV) criteria, age
of 18 to 55 years old, and ability to read and write in Per-
sian. Participants were excluded if they were enrolled in
MMT, self - reported or tested positive for opiates, opioid,
crack - heroin, and cannabis on a rapid urine test, reported
any major medical or psychiatric disorders, if they were
pregnant or not willing to use contraception during the
study trial period, had inability to adhere to scheduled fol-
low - up visits, or had any history of adverse reactions to
buprenorphine. Among the initial 28 patients that under-
went formal screening, seven (25%) were ineligible to enter
the study due to enrollment in MMT (N = 4) and inability to
adhere to scheduled follow - up visits (N = 3) (see Figure 1).
3.3. Questionnaires
3.3.1. Cognitive Abilities Questionnaire (CAQ)
The Cognitive Abilities Questionnaire (CAQ) consists of
30 items rated on a five - point Likert scale in Persian, to
evaluate seven cognitive domains, including memory, in-
hibitory control and selective attention, decision making,
planning, sustained attention, social cognition, and cogni-
tive flexibility. The internal consistency (Cronbach’s alpha)
was 0.834 and test - retest reliability was at P < 0.01 (14).
3.3.2. Leeds Dependence Questionnaire (LDQ)
The Leeds Dependence Questionnaire (LDQ) consists
of 10 items rated on a four - point Likert scale evaluating
dependency upon a variety of substances and is sensitive
through the range from mild to severe dependence. The
LDQ has a good level of internal consistency (Cronbach’s
alpha = 0.94) and test-retest reliability (r = 0.95). However,
no specific cut - off score has been established to indicate
dependence (15).
3.3.3. Obsessive Compulsive Drug Use Scale (OCDUS)
The Persian - validated version of Obsessive Compul-
sive Drug Use Scale (OCDUS) is a self - completed question-
naire, which assesses periodic craving upon substances,
such as cocaine and heroin and measures three compo-
nents of drug thoughts, desire to use drug, and resis-
tance against thoughts and decisions to use drugs, and
each question contains of five grade options, which are re-
sponded according to the participant’s experiences during
the previous week (16).
3.3.4. Addiction Severity Index (ASI - Lite)
The Lite version of Addiction Severity Index (ASI - Lite)
is a semi - structured questionnaire and consists of medi-
cal, employment/support, drug and alcohol use, legal, fam-
ily/social, and psychiatric condition. The ASI - Lite mea-
sures problematic behaviors during the individual’s life-
time, as well as the previous 30 days (17).
3.3.5. World Health Organization Quality of Life - BREF (WHO-
QOL - BREF)
The Persian - validated version of World Health Organ-
isation Quality of Life - BREF (WHOQOL - BREF) is a 26 - item
questionnaire, which consists of four subscales including
physical health, psychological health, social relationships,
and environment. Each item contains five - grade options,
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Figure 1. Participant Flow Chart for the Trial of Buprenorphine for the Treatment of MA Use Disorder
which focus on the clients’ perceptions of their well - being
during the previous two weeks. The internal consistency
(Cronbach’s alpha) is 0.75 to 0.91 for all subscales (18).
3.4. OutcomeMeasures
The primary outcome was assessment of MA use dur-
ing the six - month study period. This was measured by
rapid urinary tests, three times a week in the first three
months, and weekly during the second half of the study pe-
riod. Secondary outcomes included treatment retention,
which was calculated by the number of individuals, who
successfully finished the six - month treatment period, and
cognitive abilities, addiction severity, quality of life, MA
dependency, and craving. In addition, adverse events as-
sociated with buprenorphine were elicited during partic-
ipant’s follow - up visits with the study physician.
3.5. Statistical Analysis
Data were presented as mean± SD and frequency (%)
for quantitative and qualitative variables. Repeated mea-
sures analysis was used to further evaluate for the trend of
changes within the group. Friedman test was used for non-
parametric variables. The Friedman test is used for one -
way repeated measures analysis of variance by ranks. The
SPSS (version 19) software was used for data analysis. P val-
ues of < 0.05 were considered significant.
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3.6. Study Procedure
Baseline assessments were administered by a trained
study physician and included the CAQ, LDQ, OCDUS, ASI
- Lite, and WHOQOL - BREF. Participants were monitored
daily for one week when they underwent medical and psy-
chiatric screening, including liver function tests to evalu-
ate potential liver disease.
After enrollment, participants were inducted with
buprenorphine, starting with a dose of 0.5 mg daily to
reduce the risk of precipitated withdrawal and other ad-
verse events. Buprenorphine dosage was increased during
daily/weekly clinic visits until stabilization of MA cravings
at the maximum dose of 8 mg daily. During this period,
participants, who were unable to tolerate induction with
buprenorphine were excluded from the study (N = 2) and
were given instructions to follow - up with other addiction
treatment services.
Following stabilization, participants continued main-
tenance treatment for six months. During the first three
months, participants were evaluated three times per week
and rapid urine tests were conducted for benzodiazepine,
opioids, and MA. During months four to six, follow - up
intervals were limited to weekly visits. Participants were
also provided with brief cognitive behavioral therapy (19)
during weekly appointments by a trained Psychologist. All
questionnaires, except ASI - Lite, were rechecked on the
fourth, eighth and twelfth week visits. Moreover, cognitive
abilities were rechecked on the 24th week visits. The ASI -
Lite were checked only on baseline and 12th week visits.
At the sixth month follow up visits, buprenorphine
dosages were tapered over several weeks based on the Ira-
nian protocol for buprenorphine treatment. However, par-
ticipants were given the option to continue treatment with
buprenorphine maintenance therapy with an addiction
treatment program.
4. Results
4.1. Demographics and Drug Use Details
The majority of participants (84.2%) were male and
married (68.4%), with a mean age of 32.36 years (SD + 7.58).
The mean duration of MA use was 35.73 months (SD + 27.34)
with a mean dose of 1.00 grams daily (SD + 1.10). Most
participants had a history of opioid use (89.5%), including
opium and heroin, yet none received buprenorphine in the
past for the treatment of opioid use disorder. Nearly half of
the participants reported having been prescribed pharma-
cotherapy for MA (47.4%), including bupropion, sertraline,
and sodium valproate (see Table 1). The duration of treat-
ment and follow up in the current study was six months
(175 days). According to Figure 1, two participants were ex-
cluded from the study because of adverse medication - re-
lated events, including nausea and vomiting. Fifteen par-
ticipants (78.94%) remained in the treatment at six months.
Table 1. Baseline Socio - Demographic Characteristics of Recruited Subjects (N = 19).
Characteristics Number Percentage
Male 16 84.2
Marital status
Single 6 31.6
Married 13 68.4
Education
Elementary 3 15.8
Diploma 10 52.6
Bachelor 6 31.6
Occupation
Unemployment 5 26.3
Self - employer 3 15.8
House wife 2 10.5
Worker 5 26.3
Driver 1 5.3
Student 3 15.8
Pervious treatment history forMA
dependency
Self - try 3 15.8
Outpatient with Psychotherapy 7 36.8
Outpatient with Pharmacotherapy 9 47.4
Residential Programs 8 42.1
Life time pervious history of other
substances abuse
Opium 17 89.5
Heroin 4 21.1
Crack - Heroin 3 14.3
Alcohol 3 15.8
Cannabis 5 26.3
Mean(SD) Median (IQR)
Age (years) 32.36 (7.58) 35.00 (12.00)
Duration ofMA abuse (months) 35.73 (27.34) 15.00 (27.00)
MAdose (gr/daily) 1.00 (1.10) 1.00 (0.75)
Repeated measures analysis demonstrated statistically
significant reductions in all domains of OCDUS during the
study period (see Figure 2). In addition, MA dependency re-
vealed statistically significant reductions in the degree of
MA dependence throughout the study (P < 0.01).
4 Iran J Psychiatry Behav Sci. 2018; 12(2):e11529.
Shariatirad S et al.
25
20
15
10
5
0
M
ea
n
 D
eg
re
e 
o
f O
C
D
U
S 
Su
b
sc
al
es
Thoughts
Desire
Resistance
Thoughts
Desire
Resistance
Baseline
19.42
11.73
6.1
Week 
11.94 
7.73 
3.57 
Wee k 8 
11.42 
6.84 
3.47 
Week 12 
9.25 
5.5 
3 
Figure 2. Reduction of Craving Self - Report in Obsessive Compulsive Drug Use Scale Subscales over Time
4.2. Illicit Drug Use
There was a significant reduction in rates of MA and
opioid-positive urine drug screens (see Figure 3). Impor-
tantly, relapses to MA was not significant (P < 0.771) based
on the Friedman test, thus the post hoc analysis was not ap-
plicable in this case.
4.3. Health Status
Following the study, addiction severity showed signifi-
cant reductions in drug, family, and psychiatric status sub-
scales (see Table 2). Also, quality of life had significant im-
provements in all subscales of the WHOQOL - BREF (see Ta-
ble 2).
Repeated measures analysis showed significant im-
provements in five cognitive domains, including memory,
inhibitory control and selective attention, decision mak-
ing, planning, sustained attention, and also in the total
score. The changes in social cognition, cognitive flexibility
and the total number were not significant (see Table 2).
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Figure3. The Percentage of Negative Rapid Urinary Tests for Methamphetamine and
Morphine over Time
Moreover, only five mild adverse events were recorded
during the study, all of which improved after 48 hours.
These adverse events included nausea, dizziness, hiccups,
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Table 2. Mean Degree of ASI - Lite Subscales, LDQ, OCDUS Subscales, WHOQOL - BREF Subscales and CAQ Subscales over Time
Baseline Week 4 Week 8 Week 12 Week 24 P Value
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Median(IQR) Median(IQR) Median(IQR) Median(IQR) Median(IQR)
ASI - Lite Subscales
Medical 0.22 (3.62) - - 0.06 (0.16) - 0.086
0.00 (0.66) 0.00 (0.08)
Employment 0.45 (0.38) - - 0.45 (0.41) - 0.986
0.50 (0.75) 0.08 (0.57)
Drug 0.34 (0.68) - - 0.00 (0.02) - 0.000a
0.30 (0.07) 0.00 (0.00)
Legal 0.04 (0.10) - - 0.00 (0.00) - 0.077
0.00 (0.10) 0.00 (0.00)
Family 0.65 (0.19) - - 0.19 (0.21) - 0.000a
0.72 (0.21) 0.21 (0.36)
Psychiatric 0.55 (0.10) - - 0.10 (0.18) - 0.000a
0.59 (0.13) 0.16 (0.26)
LDQ 14.52 (3.94) 5.57 (5.65) 4.31 (4.97) 3.18 (3.60) - 0.000a
14.00 (5.00) 4.00 (8.00) 3.00 (5.00) 1.00 (7.00) -
OCDUS Subscales
Thoughts 19.42 (4.12) 11.94 (5.80) 11.42 (4.77) 9.25 (3.51) - 0.000a
20.00 (5.00) 10.00 (6.00) 10.00 (9.00) 9.00 (5.00) -
Desire 11.73 (3.73) 7.73 (3.52) 6.84 (2.47) 5.50 (1.41) - 0.000a
11.00 (6.00) 6.00 (5.00) 7.00 (4.00) 6.00 (3.00) -
Resistance 6.10 (1.48) 3.57 (1.67) 3.47 (1.64) 3.00 (1.50) - 0.000a
6.00 (3.00) 3.00 (3.00) 3.00 (1.00) 2.00 (1.00) -
WHOQOL - BREF Subscales
Physical 17.00 (2.92) 18.94 (3.43) 20.21 (3.89) 20.43 (4.83) - 0.002a
17.00 (6.00) 19.00 (7.00) 21.00 (6.00) 21.00 (7.00) -
Psychological 19.05 (3.77) 22.57 (5.13) 23.68 (6.09) 24.81 (5.64) - 0.000a
19.00 (7.00) 21.00 (7.00) 25.00 (8.00) 25.00 (5.00) -
Social 7.84 (2.14) 10.52 (5.40) 10.84 (4.84) 11.06 (2.51) - 0.006a
8.00 (3.00) 10.00 (6.00) 10.00 (5.00) 11.00 (3.00) -
Environmental 23.73 (4.61) 24.31 (8.21) 24.73 (7.33) 28.62 (6.50) - 0.012a
25.00 (6.00) 27.00 (18.00) 26.00 (12.00) 28.00 (11.00) -
CAQ Subscales
Memory 23.00 (4.72) 25.82 (3.95) 26.44 (3.83) 27.00 (4.11) 28.75 (2.86) 0.000a
25.00 (6.00) 28.00 (3.00) 28.00 (2.00) 29.00 (2.00) 30.00 (1.00)
Inhibitory control & selective attention 19.16 (5.85) 22.58 (5.36) 23.27 (3.92) 24.00 (4.96) 26.50 (2.81) 0.000a
20.00 (9.00) 25.00 (8.00) 25.00 (5.00) 26.00 (5.00) 27.00 (4.00)
Decision making 14.44 (4.71) 17.94 (4.73) 18.11 (4.98) 19.00 (5.57) 20.66 (5.56) 0.001a
14.00 (6.00) 21.00 (9.00) 18.00 (8.00) 23.00 (7.00) 22.00 (5.00)
Planning 8.00 (2.95) 10.88 (3.03) 11.94 (3.07) 12.50 (2.44) 12.83 (3.61) 0.000a
9.00 (6.00) 14.00 (4.00) 14.00 (3.00) 13.00 (5.00) 14.00 (4.00)
Sustain attention 9.22 (3.13) 10.64 (3.16) 12.00 (3.12) 12.14 (2.41) 13.08 (2.23) 0.001a
9.00 (5.00) 13.00 (4.00) 13.00 (3.00) 13.00 (4.00) 13.00 (2.00)
Social cognition 11.50 (2.79) 11.82 (2.74) 11.11 (2.92) 10.92 (3.12) 11.66 (3.05) 0.726
12.00 (5.00) 12.00 (5.00) 12.00 (4.00) 11.00 (7.00) 12.00 (6.00)
Cognitive flexibility 11.72 (4.44) 13.11 (4.91) 15.05 (3.94) 15.07 (4.48) 17.33 (2.87) 0.157
12.00 (5.00) 15.00 (10.00) 16.00 (2.00) 16.00 (8.00) 18.00 (3.00)
Total score 96.94 (21.44) 112.29 (20.78) 117.94 (15.10) 120.64 (19.58) 130.50 (17.87) 0.073
98.00 (39.00) 122.00 (33.00) 129.00 (14.00) 128.00 (28.00) 138.00 (22.00)
aDenotes a statistically significant difference.
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itching and headache and are presented in Table 3.
Table 3. Adverse Events of Buprenorphine Noted during the Study
Signs Numbers Percentage
Nausea 3 15.78
Dizziness 1 5.26
Hiccup 1 5.26
Itching 1 5.26
Headache 1 5.26
5. Discussion
The principal finding on the treatment of MA use disor-
der in this study was a reduction in MA use, high retention
in treatment, improvement in the addiction severity index,
and quality of life during the study. Moreover, it seems
buprenorphine’s attenuating effect on MA craving and im-
proved cognitive functioning were also positive findings.
Buprenorphine is a partial mu opioid receptor agonist
and a Kappa Opioid Receptor (KOR) antagonist. Lab stud-
ies suggest that mu opioid receptor agonist activity with
buprenorphine could result in lower MA consumption (20,
21). Moreover, KOR activation leads to dysphoria and also
provokes stress - induced drug craving (22), thus it seems
that buprenorphine could diminish drug craving by antag-
onistic effects on KOR. In addition, buprenorphine is also a
partial agonist of nociceptin/orphanin FQ (N/OFQ) recep-
tors (10), which has been found to block the rewarding ef-
fects of cocaine by reducing dopamine release (23). Lastly,
buprenorphine attenuates MA - induced dopamine peak
effect and it imposes a ceiling effect on dopamine release
following MA use (10).
This study also described statistically significant
changes in several subscales of ASI - Lite. These include
drug, family, and psychiatric subscales. In addition, signif-
icant changes were observed in all subscales of WHOQOL
- BREF, including physical health, psychological health,
social relationship, and environmental health. These
significant changes in both quality of life and addiction
severity were similar to the results described in a multi-
site clinical trial, which assessed Opioid Substitution
Treatment (OST) in 13 treatment programs in seven low
and middle income countries (24). The quality of life and
addiction severity scales are important findings that are
associated with improved retention (25).
It is known that MA use is associated with impaired
cognitive functioning. According to these results, memory,
inhibitory control and selective attention, decision mak-
ing, planning, sustained attention, and cognitive flexibil-
ity improved following the study. Prior studies have de-
scribed reduced cognitive deficits among patients receiv-
ing buprenorphine compared to methadone (26) and im-
provement of working memory. These findings may be at-
tributed to the KOR antagonistic effects of buprenorphine
on prefrontal dopamine tone (27).
This study was similar to a prior trial by Salehi et al.
that assessed the impact of buprenorphine on MA crav-
ings (13). Although both studies showed attenuation of
MA craving, there were some differences. Salehi et al. dis-
pensed to maximum dose of buprenorphine (6 mg daily)
compared to this study (1 mg daily), in which doses were
adjusted based on participants’ self - reported MA crav-
ings. This study also administered additional survey in-
struments, including ASI - Lite, WHOQOL - BREF, LDQ, OC-
DUS, and CAQ. These additional findings are critical in as-
sessing factors that may influence retention in treatment
and abstinence. Moreover, Salehi et al. combined matrix
therapy with buprenorphine, while the current study re-
placed the matrix model with brief cognitive behavioral
therapy. Brief cognitive behavioral therapy was integrated
to buprenorphine treatment, because of lower expenses
and greater feasibility.
There are several limitations for the use of buprenor-
phine treatment for MA use disorder: First of all, this clini-
cal study was a non - randomized, non - blinded, small sam-
ple sized observational study that did not use intention to
treat analysis. In addition, these findings may not be gen-
eralizable to other clinical populations since this research
only studied Iranian participants.
Secondly, participants were closely monitored three
times weekly during weekly visits, which many clinical set-
tings may not be able to offer. This study also provided
brief cognitive behavioral therapy yet was unable to iso-
late the impact of buprenorphine without its associated
brief cognitive behavioral therapy. In addition, partici-
pants were followed for six months and this short study
period may be insufficient to demonstrate the long - term
clinical impact.
In addition, the partial - mu receptor activity of
buprenorphine will lead to opioid dependence in MA
users. A method to minimize opioid dependence among
MA users may be to attenuate the mu action of buprenor-
phine by co - administering a mu receptor antagonist,
such as naltrexone (28). However, some studies showed
that naltrexone has poor compliance and retention rate
among opioid users (29, 30) and it seems this low adher-
ence to naltrexone among opioid users, is due to depres-
sive symptoms and dysphoria (31). Despite recent studies,
which showed that depression can not be considered as a
common adverse effect of naltrexone (32), yet naltrexone
still had a lesser retention rate compared to other medi-
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cal treatments, such as buprenorphine/naloxone, in Iran
(33). Moreover, besides the successful preclinical studies of
combination of buprenorphine and naltrexone on self - ad-
ministration of cocaine without inducing physical depen-
dence in rats (28), the correct ratio of buprenorphine and
naltrexone for acceptable clinical response in humans is
unknown. Nonetheless, buprenorphine shows promising
effects on decreasing cocaine use among concomitant opi-
ate and cocaine users (34). Moreover, buprenorphine plus
naloxone in combination with naltrexone may be associ-
ated with reductions in cocaine use among cocaine users
(35) and may be helpful in MA use disorder. Although clin-
ical evidence supporting the treatment of pure MA users
with buprenorphine are not sufficient, yet buprenorphine
can be a suitable treatment for MA users, who co - use opi-
ates.
5.1. Conclusion
These preliminary results describe the safety and po-
tential clinical impact of buprenorphine in attenuating
MA craving, and also its promising effects on cognitive im-
pairment in MA users. Furthermore, there are some obser-
vations from the key informant that buprenorphine can be
regarded as a harm reduction intervention in some com-
munities because it leads to a close relationship between
the treatment team and the patient; this role is especially
important in communities, in which people, as a result of
cultural beliefs, do not accept a therapy, which only con-
sists of counseling and no medications.
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